Andrzej Jakubowiak

Andrzej Jakubowiak

UNVERIFIED PROFILE

Are you Andrzej Jakubowiak?   Register this Author

Register author
Andrzej Jakubowiak

Andrzej Jakubowiak

Publications by authors named "Andrzej Jakubowiak"

Are you Andrzej Jakubowiak?   Register this Author

68Publications

2684Reads

31Profile Views

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.

Leukemia 2019 Sep 24;33(9):2127-2143. Epub 2019 Jul 24.

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0517-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756042PMC
September 2019

A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia.

Clin Cancer Res 2019 Aug 29;25(16):4907-4916. Epub 2019 May 29.

Myeloma Research, Sarah Cannon Research Institute, Nashville, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3728DOI Listing
August 2019

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.

J Manag Care Spec Pharm 2018 07;24(7):711-712

4 Myeloma Program University of Chicago Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18553/jmcp.2018.24.7.711DOI Listing
July 2018

Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 17;36(8):728-734. Epub 2018 Jan 17.

David S. Siegel, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Hartmut Goldschmidt, Heidelberg Medical University and National Center of Tumor Diseases, Heidelberg, Germany; Andrzej Jakubowiak, University of Chicago Medicine, Chicago, IL; Jesus San-Miguel, Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona, Spain; Mihaela Obreja and Julie Blaedel, Amgen, Thousand Oaks, CA; and A. Keith Stewart, Mayo Clinic, Scottsdale, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.5032DOI Listing
March 2018

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.

J Clin Oncol 2018 03 30;36(9):859-866. Epub 2018 Jan 30.

Dan T. Vogl, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; David Dingli, Mayo Clinic, Rochester, MN; Robert Frank Cornell, Vanderbilt University Medical Center, Nashville, TN; Carol Ann Huff, Johns Hopkins University, Baltimore, MD; Sundar Jagannath, Tisch Cancer Institute, Mount Sinai School of Medicine; David Kaminetzky, New York University Langone Medical Center; Ajai Chari, Icahn School of Medicine at Mount Sanai, New York, NY; Divaya Bhutani and Jeffrey Zonder, Karmanos Cancer Institute, Wayne State University, Detroit; Craig Cole, University of Michigan, Ann Arbor, MI; Rachid Baz, H. Lee Moffitt Cancer Center and Research Institute, Tampa; James E. Hoffman, Sylvester Cancer Center, University of Miami, Miami, FL; Ajay Nooka, Winship Cancer Institute, Emory University, Atlanta, GA; Joshua Richter and David Siegel, John Theurer Cancer Center at the Hackensack University Medical Center, Hackensack, NJ; Ravi Vij, Washington University School of Medicine, St Louis, MO; Andrzej Jakubowiak, University of Chicago Medical Center, Chicago, IL; Rafat Abonour, Indiana University Cancer Center, Indianapolis, IN; Gary Schiller, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA; Terri L. Parker, Yale School of Medicine, New Haven, CT; Luciano J. Costa, University of Alabama at Birmingham, Birmingham, AL; Andrew J. Yee, Massachusetts General Hospital Cancer Center, Boston; Michael Kauffman, Sharon Shacham, Jean-Richard Saint-Martin, Carla D. Picklesimer, and Cassandra Choe-Juliak, Karyopharm Therapeutics, Newton, MA; Rafael Fonseca, Scott Van Wier, Gregory Ahmann, Ilsel Lopez, and A. Keith Stewart, Mayo Clinic of Arizona, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5207DOI Listing
March 2018

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

N Engl J Med 2018 02 12;378(6):518-528. Epub 2017 Dec 12.

From University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Cáncer, Pamplona (J.S.-M.) - both in Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera "Santa Maria," Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center, Chicago (A.J.); Würzburg University Medical Center, Würzburg, Germany (S.K.); Université Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.); Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno, Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom; the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clínica de Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); LTD "Medinvent" Institute of Health, Tbilisi, Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen Research and Development, Raritan, NJ (J.W., H.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1714678DOI Listing
February 2018

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies.

Hematology 2017 Dec 25;22(10):585-591. Epub 2017 May 25.

c Department of Clinical Development , Amgen Inc., One Amgen Center Drive , Thousand Oaks , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10245332.2017.1328165DOI Listing
December 2017

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.

Leuk Lymphoma 2015 12;56(10):2959-61. Epub 2015 May 12.

g John Theurer Cancer Center at Hackensack University Medical Center , Hackensack , NJ , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1020801DOI Listing
September 2016

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview.

Cancer Treat Rev 2014 Jul 1;40(6):781-90. Epub 2014 Mar 1.

Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637-6613, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.02.005DOI Listing
July 2014

Current strategies for treatment of relapsed/refractory multiple myeloma.

Expert Rev Hematol 2014 Feb 29;7(1):97-111. Epub 2014 Jan 29.

Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.882764DOI Listing
February 2014

Introduction: recent advances in the understanding and management of multiple myeloma.

Semin Oncol 2013 Oct;40(5):535-6

The University of ChicagoChicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.08.003DOI Listing
October 2013

Evolving strategies in the initial treatment of multiple myeloma.

Semin Oncol 2013 Oct;40(5):592-601

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL; Comprehensive Cancer Center, The University of Chicago, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.08.002DOI Listing
October 2013

Current approaches to the initial treatment of symptomatic multiple myeloma.

Int J Hematol Oncol 2013 Feb;2(1)

Section of Hematology/Oncology, Department of Medicine & Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/ijh.13.3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839860PMC
February 2013

Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction.

Semin Hematol 2012 Jul;49 Suppl 1:S1-2

University of Chicago Medical Center, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2012.05.002DOI Listing
July 2012

Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.

Semin Hematol 2012 Jul;49 Suppl 1:S16-32

University of Chicago Medical Center, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2012.05.003DOI Listing
July 2012

Monoclonal antibodies in the treatment of multiple myeloma.

Br J Haematol 2011 Sep 21;154(6):745-54. Epub 2011 Jul 21.

Dana-Farber Cancer Institute, Boston, MA, USADepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USACentre Rene Gauducheau, Nantes, France.

View Article

Download full-text PDF

Source
http://deepblue.lib.umich.edu/bitstream/handle/2027.42/86883
Web Search
http://doi.wiley.com/10.1111/j.1365-2141.2011.08790.x
Publisher Site
http://dx.doi.org/10.1111/j.1365-2141.2011.08790.xDOI Listing
September 2011

Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.

Clin Adv Hematol Oncol 2011 Apr;9(4):1-15

Chief Myeloma Division, John Theuer Cancer Center, Hackensack, New Jersey, USA.

View Article

Download full-text PDF

Source
April 2011

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.

Leuk Lymphoma 2010 Jul;51(7):1178-87

Department of Neurosciences and Biomedical Technologies, University of Milan-Bicocca, Monza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.483303DOI Listing
July 2010

Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.

J Clin Oncol 2009 Oct 8;27(30):5015-22. Epub 2009 Sep 8.

Comprehensive Cancer Center, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109-5936, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.5370DOI Listing
October 2009

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia.

Blood 2008 Sep 24;112(5):1993-2003. Epub 2008 Apr 24.

Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109-0936, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-07-099432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518900PMC
September 2008

Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.

Proc Natl Acad Sci U S A 2007 Dec 27;104(49):19488-93. Epub 2007 Nov 27.

Department of Dermatology, Comprehensive Cancer Center, and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0708380104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2148316PMC
December 2007

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

Clin Adv Hematol Oncol 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2

Hematology/Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA,

View Article

Download full-text PDF

Source
http://myeloma.org/pdfs/2007%20Cl%20Adv%20Hem%20Onc-%20A%20P
Web Search
October 2007

Cladribine underdosing in hairy-cell leukemia: a cause for apparent response failure.

Leuk Lymphoma 2002 Feb;43(2):365-7

Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1080/1042819029000617
Publisher Site
http://dx.doi.org/10.1080/10428190290006170DOI Listing
February 2002